TaiMed Biologics Inc. (4147.TWO)
- Previous Close
79.50 - Open
78.70 - Bid 78.60 x --
- Ask 79.00 x --
- Day's Range
78.50 - 79.00 - 52 Week Range
65.90 - 108.50 - Volume
155,676 - Avg. Volume
1,882,895 - Market Cap (intraday)
21.573B - Beta (5Y Monthly) -0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.75 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
141.67
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment. In addition, it offers contract development and manufacturing services. The company has a research and development agreement for Trogarzo TMB-355 with Genentech and Biogen Inc., and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei City, Taiwan.
www.taimedbiologics.comRecent News: 4147.TWO
View MorePerformance Overview: 4147.TWO
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4147.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4147.TWO
View MoreValuation Measures
Market Cap
21.71B
Enterprise Value
20.58B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.95
Price/Book (mrq)
5.40
Enterprise Value/Revenue
33.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-33.08%
Return on Assets (ttm)
-3.55%
Return on Equity (ttm)
-6.13%
Revenue (ttm)
610.16M
Net Income Avi to Common (ttm)
-201.83M
Diluted EPS (ttm)
-0.75
Balance Sheet and Cash Flow
Total Cash (mrq)
1.65B
Total Debt/Equity (mrq)
12.99%
Levered Free Cash Flow (ttm)
-268.47M